Recent Price Movement and Market Context
On 24 Nov 2025, Vivo Bio Tech . touched Rs.30.11, its lowest price point in the past year. This level contrasts sharply with its 52-week high of Rs.56.90, illustrating a substantial contraction in market valuation. Over the last eight trading days, the stock has delivered a cumulative return of -10.85%, underperforming its sector by approximately 0.29% on the day of the new low.
The stock is currently trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, indicating sustained downward momentum. This technical positioning suggests that the stock has not found short-term support levels to halt the decline.
Meanwhile, the broader market environment presents a contrasting picture. The Sensex opened 88.12 points higher and was trading at 85,466.86, up 0.28% on the same day. The benchmark index is nearing its 52-week high of 85,801.70, just 0.39% away, and has recorded a 2.7% gain over the past three weeks. Mega-cap stocks have been leading this rally, with the Sensex trading above its 50-day moving average, which itself is positioned above the 200-day moving average, signalling a bullish trend for the broader market.
This week's disclosed pick, a Large Cap from NBFC, comes with precise Target Price and analysis. Check if you're positioned right for this opportunity!
- - Precise target price set
- - Weekly selection live
- - Position check opportunity
Long-Term Performance and Financial Indicators
Over the past year, Vivo Bio Tech . has recorded a return of -19.65%, contrasting with the Sensex’s positive 8.03% return during the same period. This underperformance extends over a longer horizon, with the stock trailing the BSE500 index in each of the last three annual periods.
Examining the company’s financial fundamentals reveals several areas of concern. The compound annual growth rate (CAGR) of net sales over the last five years stands at -0.92%, indicating a contraction in revenue generation. The company’s ability to service debt is reflected in an average EBIT to interest ratio of 1.95, which suggests limited coverage of interest expenses by operating earnings.
Profitability metrics also highlight challenges. The average return on equity (ROE) is 7.49%, a figure that points to modest profitability relative to shareholders’ funds. Additionally, over the past year, profits have declined by 42.5%, further underscoring pressures on earnings despite some positive quarterly results.
Quarterly Highlights and Valuation Metrics
Despite the overall downtrend, certain quarterly figures show pockets of strength. The latest quarter recorded net sales at Rs.12.51 crores, the highest in recent periods. Profit after tax (PAT) for the latest six months reached Rs.2.40 crores, representing a growth of 163.74% compared to previous periods. The operating profit to interest coverage ratio for the quarter was 3.65 times, the highest recorded, indicating improved short-term debt servicing capacity.
From a valuation standpoint, the company’s return on capital employed (ROCE) is 9.3%, which is considered attractive relative to its enterprise value to capital employed ratio of 0.9. This suggests that the stock is trading at a discount compared to historical valuations of its peers within the Pharmaceuticals & Biotechnology sector.
Why settle for Vivo Bio Tech .? SwitchER evaluates this Pharmaceuticals & Biotechnology micro-cap against peers, other sectors, and market caps to find you superior investment opportunities!
- - Comprehensive evaluation done
- - Superior opportunities identified
- - Smart switching enabled
Shareholding and Sectoral Positioning
Vivo Bio Tech . operates within the Pharmaceuticals & Biotechnology industry and sector, which has seen mixed performance in recent months. The majority of the company’s shares are held by non-institutional investors, which may influence trading patterns and liquidity.
While the stock has faced downward pressure, the broader sector continues to attract attention due to ongoing developments in biotechnology and pharmaceutical innovation. However, Vivo Bio Tech .’s relative performance has lagged behind sector averages and benchmark indices.
Summary of Key Market and Financial Data
The stock’s new 52-week low of Rs.30.11 marks a significant milestone in its recent price trajectory, following an eight-day losing streak and a cumulative return decline of 10.85% during this period. Trading below all major moving averages signals continued bearish momentum. In contrast, the Sensex and mega-cap stocks have shown resilience and gains over the same timeframe.
Financially, the company’s net sales have shown a slight negative growth trend over five years, with profitability and debt servicing metrics indicating modest performance. Quarterly results reveal some improvement in sales and profit after tax, but these have not translated into a sustained recovery in share price.
Valuation metrics suggest the stock is trading at a discount relative to peers, supported by a reasonable ROCE and enterprise value to capital employed ratio. Nonetheless, the stock’s performance relative to the benchmark indices and sector peers remains subdued.
Limited Time Only! Subscribe for Rs. 12,999 and get 1 Year of MojoOne + an Additional Year Completely FREE. Don't miss out on this exclusive offer. Claim Your Free Year →
